[Featured Stock] Daehwa Pharmaceutical Rises for Second Day on News of Oral Anticancer Drug Export to China

Mid-sized pharmaceutical company Daehwa Pharmaceutical showed strong performance for two consecutive days following news of exporting oral anticancer drugs to China.

On the 11th, Daehwa Pharmaceutical's stock closed at 15,720 KRW, up 15.67% compared to the previous trading day. It marked a second consecutive day of gains.

The buying momentum is attributed to the news that the global first oral paclitaxel formulation, Liporaxel solution (Liporaxel), will begin full-scale sales in China. Since mid-last month, Daehwa Pharmaceutical has been selling Liporaxel locally through its Chinese partner company, Haihe Bio Pharma. Liporaxel is an improved new drug and an oral formulation of Taxol (active ingredient paclitaxel, intravenous injection), a blockbuster anticancer drug with a global market size reaching 5 trillion KRW.

Daehwa Pharmaceutical plans to expand Liporaxel's indications from gastric cancer to metastatic and recurrent breast cancer, aiming to increase its market share in the Chinese anticancer drug market.